Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Related Videos
Experts on renal cell carcinoma
Experts on renal cell carcinoma
Matthew Galsky, MD
Expert on prostate cancer
Jonathan Chatzkel, MD
David A. Braun, MD, PhD
Paul L. Nguyen, MD, senior physician, director, Genitourinary Clinical Center for Radiation Oncology, Dana-Farber Cancer Institute, professor of radiation oncology, Harvard Medical School,
Guru P. Sonpavde, MD, medical director, Genitourinary (GU) Oncology, assistant director, Clinical Research Unit, Christopher K. Glanz Chair, Bladder Cancer Research, AdventHealth Cancer Institute
Related Content